INmune Bio Inc. (NASDAQ: INMB) reported a net loss of $45.9 million for 2025, compared to $42.1 million in 2024, according to financial results announced by the biotechnology company.

The company plans to submit a Marketing Authorization Application for its CORDStrom™ treatment to the UK's MHRA in mid-summer 2026, followed by European and FDA filings in the fourth quarter. CORDStrom™ is being developed for recessive dystrophic epidermolysis bullosa.

Research and development expenses decreased to $20.7 million in 2025 from $33.2 million in 2024. The company recorded a $16.5 million impairment of acquired in-process research and development intangible assets during 2025.

INmune Bio raised $27.5 million in net proceeds from selling 4.3 million shares of common stock during 2025. The company reported $24.8 million in cash and cash equivalents as of December 31, 2025, and estimates this provides funding through the first quarter of 2027.

The company received a $3.6 million Australian R&D rebate in January 2026. General and administrative expenses increased slightly to $10.3 million in 2025 from $9.5 million in 2024.

For its XPro™ platform targeting Alzheimer's disease, INmune Bio announced FDA alignment for an adaptive Phase 2b/3 registrational pathway. The company's INKmune® platform met primary and two of three secondary endpoints in its CARE-PC trial for metastatic castration-resistant prostate cancer.

INmune Bio had approximately 26.6 million common shares outstanding as of December 31, 2025. The company is scheduled to host a conference call to discuss results.